possible that in some epileptic patients treated with carbamazepine the signs of water intoxication are mistakenly attributed to direct drug toxicity (Stephens et al., 1977) .
Relatively little information, however, is available on the incidence of carbamazepine-induced hyponatraemia in epileptic patients. Henry et al. (1977) found five cases of hyponatraemia among 16 carbamazepine-treated patients with epilepsy or trigeminal neuralgia, and described a negative correlation between plasma sodium concentration and daily carbamazepine dose above 700 mg. On the other hand, none of the 26 carbamazepinetreated epileptic children studied by Helin et al. (1977) had abnormal levels of electrolytes.
In the present study we have determined plasma sodium and osmolality in a large population of epileptic patients receiving chronic treatment with carbamazepine. Fifty patients treated with other anticonvulsant drugs were included in the study as a control group. In order to investigate the integrity of the homeostatic mechanisms which regulate water balance during carbamazepine therapy, free water clearance after administration of a water load has been measured in a group of patients on carbamazepine and in a control group of normal subjects not receiving drug therapy. When all patients were considered, a negative correlation was found between plasma sodium concentration and both the serum concentration and daily dose of carbamazepine. Although this was significantly different from zero (P<0.005), the multiple correlation coefficients were low (-0.35 and -0.34 respectively), which meant that only a small proportion of the interindividual variation in plasma sodium concentration was explained by the regression line. However, when plasma sodium concentration values were plotted against serum carbamazepine concentration in the 13 patients treated with carbamazepine alone (Fig. 3) , a considerably higher coefficient of correlation was found (-0.78, P<0.002) In six patients the serum carbanmazepine concentration exceeded the upper limit of the therapeutic range of 16-40 ,umol/l. Four of them were on monotherapy and two were hyponatraemic. There was a significant correlation between daily dose and serum carbamazepine concentration but the values were widely scattered (Fig. 4) .
No signs suggestive of water intoxication were observed in the hyponatraemic patients, apart from drowsiness and confusion in one which could have been caused by concurrent drug intoxication. These signs cleared when the hyponatraemia was corrected by reducing the dose of carbamazepine. In the remaining patients, the electrolyte disturbance was corrected by administering frusemide 80 mg daily. An improvement in the control of seizures followed frusemide administration in one.
WATER LOAD TESTS
Free water clearance values (mean+SD) determined over 30 min periods after oral administration of a water load in both healthy subjects and epileptic patients are shown in Fig. 5 . Thirty minutes after the start of the test, the free water clearance reversed from negative to positive in all three times lower than those observed in healthy subjects. The difference was statistically significant at 0.5 and 1.0 h after the start of the test. All normal subjects showed a similar response to the water load, but marked interindividual differences were found among the patients. Two of the patients had a normal response, while in two (one of whom is illustrated in Fig. 6 ) the free water clearance showed little or no change after the water load. In these two subjects plasma sodium concentration and osmolality were found to be low in the sample taken at the end of the test; the remaining four patients and the six control subjects had normal values. The two hyponatraemic patients complained of malaise and drowsiness and one had an epileptic attack at the 30 end of the test. In each, a marked diuretic response followed the oral administration of 80 mg of frusemide (Fig. 6 ).
Discussion
Carbamazepine has been shown to have an antidiuretic effect in patients with diabetes insipidus (Kimura et al., 1974; Meinders et al., 1974; Wales, 1975; Smith et al., 1977) , trigeminal neuralgia (Rado, 1973; Henry et al., 1977;  Stephens et at., 1977) , and epilepsy (Ashton et al., 1977; Henry et al., 1977; Stephens et al., 1977) . It has been suggested that the drug acts by stimulating the release of antidiuretic hormone (ADH) from the posterior pituitary (Ashton et al., 1977) , although present evidence remains controversial (Kimura et al., 1974; Meinders et al., 1974; Wales, 1975; Smith et al., 1977 (1977) . In our patients the negative correlation between plasma sodium concentration and both the dose and serum concentration of carbamazepine, as described by Henry et al. (1977) , was confirmed. However, hyponatraemia was found in a considerably smaller proportion of our patients. A possible explanation for the discrepancy is that, in all but six of our patients, serum carbamazepine concentration was below the upper limit of the therapeutic range of 16-40 ,umol/l. At the Chalfont Centre for Epilepsy, the determination of serum carbamazepine concentration forms part of the clinical management, and the dose of the drug is usually tailored to achieve a concentration within the therapeutic range. Since there is evidence that water intoxication tends to be associated with toxic serum concentration (Ashton et al., 1977; Henry et al., 1977; Stephens et al., 1977) , the practice of drug monitoring has probably reduced the incidence of this adverse effect in our population. It is of interest in this respect that in none of the epileptic children studied by Helin et al. (1977) was the serum carbamazepine concentration clearly toxic, which may account for their negative findings.
The serum conCentrations of carbamazepine in our patients were lower than those observed by Henry et al. (1977) in spite of a similar dose range in the two series. This was probably due to the fact that most of our patients were receiving other antiepileptic drugs and these agents lower serum carbamazepine concentration by inducing its metabolism (Christiansen and Dam, 1973) . Four (31%) of the 13 patients on a single drug ("monotherapy") had toxic concentrations compared with only two (3%) of the patients on more than one drug ("polytherapy"), in spite of similar daily dosages administered to the subjects of both groups. Henry et al. (1977) did not mention the time of sampling although it is known that serum carbamazepine concentration fluctuates widely during the day even when the drug is administered in divided daily doses (Johannessen et al., 1976) . Samples were taken from our patients before the first morning dose when the concentration is generally at a trough (Johannessen et al., 1976) . The correlation between serum concentration and dose found by us has not been observed by others (Pynnonen et al., 1977) . However, the values showed a large scatter around the regression line probably because of interindividual differences in absorption and rate of metabolism.
The observation that hyponatraemia was more frequent in the patients on monotherapy and that plasma sodium and serum carbamazepine concentrations correlated more strongly in these patients suggests that other antiepileptic drugs may prevent the antidiuresis induced by carbamazepine. This antagonism may be the result of a combined pharmacokinetic and pharmacodynamic interaction-that is, reduction of serum carbamazepine concentration, as discussed above, and inhibition of ADH release from the posterior pituitary, an effect which has been documented with phenytoin (Fichman et al., 1970) .
The number of patients with hyponatraemia was too small for the effect of this disturbance on fit frequency to be assessed. In one patient the correction of hyponatraemia appeared to improve seizure control, but this could equally have been due to the anticonvulsant properties of frusemide (Ahmad et al., 1976) . However, the relationship between epilepsy and water balance appears established (McQuarrie, 1929) . Fluid restriction has been successfully employed in the treatment of epilepsy (Stubbe-Teglbjaerg, 1936) , whereas forced water intake has been used as a diagnostic test to produce seizures (McQuarrie and Peeler, 1931) . This might have been responsible for the prolonged fit in one of our patients who developed hyponatraemia after the water load test. Although the incidence of hyponatraemia in epileptic patients treated with carbamazepine is probably relatively small, many patients may be susceptible to electrolyte disturbance. Our results show that even if carbamazepine-treated subjects have a normal plasma sodium concentration and osmolality, their capacity to excrete a water load may be grossly impaired. Therefore, excessive intake of fluids-for example, several pints of beershould be particularly discouraged in patients taking the drug. We suggest that plasma sodium concentration and osmolality should be checked when symptoms like lethargy, drowsiness, and confusion or an unexplained increase in fit frequency develop in carbamazepine-treated patients, especially when the dose or the serum concentration of the drug is high. Our 
